Mrsa | Inovio Pharmaceuticals Widens Penn License Deal


Inovio Pharmaceuticals on Thursday expanded its existing license agreement with the University of Pennsylvania University of Pennsylvania Latest from The Business Journals CFO OF THE YEAR EXTRA-LARGE COMPANY PASSHE focuses on making most out of less money Miller-Keystone signs Chestnut Hill Hospital blood deal Follow this company .

The expanded agreement adds exclusive worldwide licenses for technology and intellectual property for novel DNA vaccines against prostate cancer, CMV (cytomegalovirus), malaria, hepatitis B, RSV (respiratory syncytial virus), and MRSA (methicillin-resistant staphylococcus aureus).


The amendment also encompasses a new optimized IL-12 cytokine gene adjuvant.

The new DNA vaccine candidates and technology were developed in the laboratory of David B. Weiner , a Penn professor and pioneer in the field of DNA vaccines, Weiner is chairman of scientific advisory board at Inovio (AMEX:INO) of Blue Bell, Pa.

Financial


Click here to view rest of article from original site

Mrsa  by John A. Weigelt Mrsa  by John A. Weigelt

13 new from $17.61
Staphaseptic First Aid Bactericide Gel 2 Oz (56.7 G)  by Staphaseptic Staphaseptic First Aid Bactericide Gel 2 Oz (56.7 G)  by Staphaseptic

26 new from $8.49



Facebook Twitter Email